Ballicules › Drugs › Bexagliflozin
Pronunciation: bex-a-gli-FLOE-zin (bren-ZA-vee)
Mechanism of action: Bexagliflozin ballicule
Visual mnemonic: Bexagliflozin mascot“Beck's a' Brewin' gravy” SGLT2 inhibitor theme
What it is SGLT2 inhibitor causing urinary glucose and sodium loss; type 2 diabetes.
Why this one Its practical distinction is lower acquisition cost rather than proven cardiorenal superiority.
What limits it Unlike established gliflozins, it lacks cardiovascular and renal outcome evidence; genital infection and euglycemic ketoacidosis remain.
Molecular structure: Bexagliflozin
FDA-approved for
FDA label
Read the full label on DailyMed ↗
FDA dosing Population Start Target Max
Type 2 diabetes mellitus (glycemic control adjunct) Adults 20 mg QD 20 mg QD 20 mg QD
Renal Not recommended if eGFR < 30 mL/min/1.73 m2; assess renal function before initiation
Hepatic Not recommended in severe hepatic impairment
Instructions Take once daily in the morning, with or without food Do not crush or chew Correct volume depletion before initiating Withhold at least 3 days before surgery/prolonged fasting; resume when clinically stable
Available strengths
Cautions Diabetic ketoacidosis (may occur with normal glucose) — assess and discontinue if suspected Lower-limb amputation risk — monitor feet Volume depletion / acute kidney injury Genitourinary infections including urosepsis, pyelonephritis, Fournier's gangrene, genital mycotic infections Hypoglycemia with insulin/secretagogues — consider lowering their dose
Adverse reactions Female genital mycotic infections Urinary tract infection Increased urination
Pregnancy Not recommended in 2nd and 3rd trimesters (animal renal effects); data insufficient in 1st
Lactation Not recommended while breastfeeding
Cost Bexagliflozin (BRENZAVVY)
Strength #/mo generic $/mo CostPlus 20 mg tab 30 qd offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Bexagliflozin is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Generic entry 2037 est.
Principal risk It lacks the outcome data the other gliflozins carry
Classes and tags
Clinical profile
Therapeutic safety burden 2 / 4
Overdose danger 2 / 4
Weight-gain liability 0 / 4
Sedation liability 0 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 0 / 4
Embryofetal risk 2 / 4
Legacy pregnancy category Not assigned — PLLR-era drug
Defining liability Agent-specific hypoglycemia, ketoacidosis, volume, renal or gastrointestinal toxicity.
Open Bexagliflozin in the interactive console ↗
Memory aids: interaction avatars
Box: minimal PK interactions
Open Bexagliflozin in the interactive console ↗